Bile Acid Sequestrants Market Analysis

  • Report ID: 5452
  • Published Date: Dec 11, 2023
  • Report Format: PDF, PPT

Bile Acid Sequestrants Market Analysis

Type (Colestid, Colestipol, Prevalite, Questran)

The colestipol segment is anticipated to hold 35% share of the global bile acid sequestrants market by the end of 2036 and this growth will be wheeled by its extensive use in reducing bad cholesterol. Colestipol is increasingly used for the therapy of basic hypercholesterolemia. It is implemented as an adjunctive treatment to dietary improvements and exercise. Daily doses of 4 to 16 grams are related to a 12 to 24% lowering in low-density lipoprotein cholesterol (LDL-C) levels. It may also lower the risk of coronary artery disease. Colestipol is also utilized off-label to cure cholestatic pruritus and irritable bowel syndrome or bile acid diarrhea. This activity reviews the symptoms, mechanism of action, negative event profile, toxicity, dosing, pharmacodynamics, and monitoring of colestipol appropriate for interprofessional team members included in maintaining primary hypercholesterolemia and related situations.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacies segment in the bile acid sequestrants market is predicted to hold the highest share of 38 % by the end of 2036. The reason behind this segment’s huge growth is that when a patient has a massive heart attack and requires more specific care and therapy, hospital pharmacies are the primary source of drugs for those people. These pharmacies also often give a bigger selection of bile acid-sequestrant medications and give patients customized dose guidelines and advice, both of which can increase patient outcomes. The global population in 2023 is 8 billion. Of these, roughly 620 million people are living with heart and circulatory diseases across the planet and are appointed to hospital pharmacies. Each year around 60 million people around the globe encounter a heart or circulatory disease. Also, as the number of hospitals globally has escalated and hyperlipidemia is becoming more general, the exercise of purchasing drugs from hospital pharmacies has become more famous.

Our in-depth analysis of the global bile acid sequestrants market includes the following segments:

  Type

  • Colestid
  • Colestipol
  • Prevalite
  • Questran

  Application

  • Hyperlipidemia
  • Liver Cirrhosis
  • Hyperthyroidism
  • T2D

  Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5452
  • Published Date: Dec 11, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of hyperlipidemia worldwide will majorly drive the market growth of the bile acid sequestrants market.

The market size of the bile acid sequestrants market is expected to get a CAGR of approximately 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Pfizer Inc., AstraZeneca Plc, Ecogene, Novartis International AG, Sanofi S.A., Amgen Inc., Merck & Co., Inc., AbbVie Inc., GlaxoSmithKline plc., Octapharma AG, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Mochida Pharmaceutical Co., Ltd., Astellas Pharma Inc.

The hospital pharmacies segment is anticipated to reap the largest market size with almost 38% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying